Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Long-term reduction in hyperglycemia in advanced type 1 diabetes: the value of induced aerobic glycolysis with BCG vaccinations.

Kühtreiber WM, Tran L, Kim T, Dybala M, Nguyen B, Plager S, Huang D, Janes S, Defusco A, Baum D, Zheng H, Faustman DL.

NPJ Vaccines. 2018 Jun 21;3:23. doi: 10.1038/s41541-018-0062-8. eCollection 2018.

2.

Structural principles of tumor necrosis factor superfamily signaling.

Vanamee ÉS, Faustman DL.

Sci Signal. 2018 Jan 2;11(511). pii: eaao4910. doi: 10.1126/scisignal.aao4910. Review.

PMID:
29295955
3.

TNFR2: A Novel Target for Cancer Immunotherapy.

Vanamee ÉS, Faustman DL.

Trends Mol Med. 2017 Nov;23(11):1037-1046. doi: 10.1016/j.molmed.2017.09.007. Epub 2017 Oct 12. Review.

PMID:
29032004
4.

TNF, TNF inducers, and TNFR2 agonists: A new path to type 1 diabetes treatment.

Faustman DL.

Diabetes Metab Res Rev. 2018 Jan;34(1). doi: 10.1002/dmrr.2941. Epub 2017 Sep 29. Review.

PMID:
28843039
5.

Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs.

Torrey H, Butterworth J, Mera T, Okubo Y, Wang L, Baum D, Defusco A, Plager S, Warden S, Huang D, Vanamee E, Foster R, Faustman DL.

Sci Signal. 2017 Jan 17;10(462). pii: eaaf8608. doi: 10.1126/scisignal.aaf8608.

PMID:
28096513
6.

Treg activation defect in type 1 diabetes: correction with TNFR2 agonism.

Okubo Y, Torrey H, Butterworth J, Zheng H, Faustman DL.

Clin Transl Immunology. 2016 Jan 8;5(1):e56. doi: 10.1038/cti.2015.43. eCollection 2016 Jan.

7.

Strategic internal covalent cross-linking of TNF produces a stable TNF trimer with improved TNFR2 signaling.

Ban L, Kuhtreiber W, Butterworth J, Okubo Y, Vanamee ÉS, Faustman DL.

Mol Cell Ther. 2015 Aug 12;3:7. doi: 10.1186/s40591-015-0044-4. eCollection 2015.

8.

Low levels of C-peptide have clinical significance for established Type 1 diabetes.

Kuhtreiber WM, Washer SL, Hsu E, Zhao M, Reinhold P 3rd, Burger D, Zheng H, Faustman DL.

Diabet Med. 2015 Oct;32(10):1346-53. doi: 10.1111/dme.12850. Epub 2015 Aug 16.

9.

Removal of donor human leukocyte antigen class I proteins with papain: translation for possible whole organ practices.

Mera T, Faustman DL.

Transplantation. 2015 Apr;99(4):724-30. doi: 10.1097/TP.0000000000000436.

PMID:
25340603
10.

Treatment of primary Sjögren syndrome with rituximab.

Faustman DL, Vivino FB, Carsons SE.

Ann Intern Med. 2014 Sep 2;161(5):376-7. doi: 10.7326/L14-5017-3. No abstract available.

PMID:
25178574
11.

Treatment for salivary gland hypofunction at both initial and advanced stages of Sjögren-like disease: a comparative study of bone marrow therapy versus spleen cell therapy with a 1-year monitoring period.

Khalili S, Faustman DL, Liu Y, Sumita Y, Blank D, Peterson A, Kodama S, Tran SD.

Cytotherapy. 2014 Mar;16(3):412-23. doi: 10.1016/j.jcyt.2013.10.006. Epub 2014 Jan 9.

PMID:
24411591
12.

TNF Receptor 2 and Disease: Autoimmunity and Regenerative Medicine.

Faustman DL, Davis M.

Front Immunol. 2013 Dec 23;4:478. doi: 10.3389/fimmu.2013.00478.

13.

Homogeneous expansion of human T-regulatory cells via tumor necrosis factor receptor 2.

Okubo Y, Mera T, Wang L, Faustman DL.

Sci Rep. 2013 Nov 6;3:3153. doi: 10.1038/srep03153.

14.

Why were we wrong for so long? The pancreas of type 1 diabetic patients commonly functions for decades.

Faustman DL.

Diabetologia. 2014 Jan;57(1):1-3. doi: 10.1007/s00125-013-3104-9. Epub 2013 Nov 5.

PMID:
24190583
15.

The Hippo signaling pathway is required for salivary gland development and its dysregulation is associated with Sjogren's syndrome.

Enger TB, Samad-Zadeh A, Bouchie MP, Skarstein K, Galtung HK, Mera T, Walker J, Menko AS, Varelas X, Faustman DL, Jensen JL, Kukuruzinska MA.

Lab Invest. 2013 Nov;93(11):1203-18. doi: 10.1038/labinvest.2013.114. Epub 2013 Sep 30.

16.

Gene expression of catalytic proteasome subunits and resistance toward proteasome inhibition of B lymphocytes from patients with primary sjogren syndrome.

Martinez-Gamboa L, Lesemann K, Kuckelkorn U, Scheffler S, Ghannam K, Hahne M, Gaber-Elsner T, Egerer K, Naumann L, Buttgereit F, Dörner T, Kloetzel PM, Burmester GR, Faustman DL, Feist E.

J Rheumatol. 2013 May;40(5):663-73. doi: 10.3899/jrheum.120680. Epub 2013 Mar 15.

PMID:
23504381
17.

EBV infection and anti-CD3 treatment for Type 1 diabetes: bad cop, good cop?

Faustman DL.

Expert Rev Clin Immunol. 2013 Feb;9(2):95-7. doi: 10.1586/eci.12.101. No abstract available.

18.

Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes.

Faustman DL, Wang L, Okubo Y, Burger D, Ban L, Man G, Zheng H, Schoenfeld D, Pompei R, Avruch J, Nathan DM.

PLoS One. 2012;7(8):e41756. doi: 10.1371/journal.pone.0041756. Epub 2012 Aug 8.

19.

Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay.

Wang L, Lovejoy NF, Faustman DL.

Diabetes Care. 2012 Mar;35(3):465-70. doi: 10.2337/dc11-1236.

20.

Novel automated blood separations validate whole cell biomarkers.

Burger DE, Wang L, Ban L, Okubo Y, Kühtreiber WM, Leichliter AK, Faustman DL.

PLoS One. 2011;6(7):e22430. doi: 10.1371/journal.pone.0022430. Epub 2011 Jul 22.

21.

Stem cells in the spleen: therapeutic potential for Sjogren's syndrome, type I diabetes, and other disorders.

Faustman DL, Davis M.

Int J Biochem Cell Biol. 2010 Oct;42(10):1576-9. doi: 10.1016/j.biocel.2010.06.012. Epub 2010 Jun 18. Review.

22.

Proteomics identifies multipotent and low oncogenic risk stem cells of the spleen.

Dieguez-Acuña F, Kodama S, Okubo Y, Paz AC, Gygi SP, Faustman DL.

Int J Biochem Cell Biol. 2010 Oct;42(10):1651-60. doi: 10.1016/j.biocel.2009.12.001. Epub 2009 Dec 18.

23.

Expression of proteasomal immunosubunit beta1i is dysregulated in inflammatory infiltrates of minor salivary glands in Sjogren's syndrome.

Morawietz L, Martinez-Gamboa L, Scheffler S, Hausdorf G, Dankof A, Kuckelkorn U, Doerner T, Egerer K, Burmester GR, Faustman DL, Feist E.

J Rheumatol. 2009 Dec;36(12):2694-703. doi: 10.3899/jrheum.081098. Epub 2009 Oct 15.

PMID:
19833746
24.

The primacy of CD8 T lymphocytes in type 1 diabetes and implications for therapies.

Faustman DL, Davis M.

J Mol Med (Berl). 2009 Dec;87(12):1173-8. doi: 10.1007/s00109-009-0516-6. Epub 2009 Aug 21. Review.

PMID:
19693476
25.

Immunotherapy on trial for new-onset type 1 diabetes.

Faustman DL.

N Engl J Med. 2008 Oct 30;359(18):1956-8. doi: 10.1056/NEJMe0807425. Epub 2008 Oct 8. No abstract available.

PMID:
18843119
26.

Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism.

Ban L, Zhang J, Wang L, Kuhtreiber W, Burger D, Faustman DL.

Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13644-9. doi: 10.1073/pnas.0803429105. Epub 2008 Aug 28.

27.

Fetal Hox11 expression patterns predict defective target organs: a novel link between developmental biology and autoimmunity.

Lonyai A, Kodama S, Burger D, Faustman DL.

Immunol Cell Biol. 2008 May-Jun;86(4):301-9. doi: 10.1038/icb.2008.6. Epub 2008 Feb 26.

28.

The promise of Hox11+ stem cells of the spleen for treating autoimmune diseases.

Lonyai A, Kodama S, Burger D, Davis M, Faustman DL.

Horm Metab Res. 2008 Feb;40(2):137-46. doi: 10.1055/s-2007-1022560. Review.

PMID:
18283632
29.

Splenectomy: a new treatment option for ALL tumors expressing Hox-11 and a means to test the stem cell hypothesis of cancer in humans.

Dieguez-Acuna FJ, Gygi SP, Davis M, Faustman DL.

Leukemia. 2007 Oct;21(10):2192-4. Epub 2007 Aug 16. No abstract available.

PMID:
17713543
30.

Permanent reversal of diabetes in NOD mice.

Faustman DL.

Science. 2007 Jul 13;317(5835):196. No abstract available.

PMID:
17626866
31.

Reversal of type 1 diabetes in mice.

Faustman DL.

N Engl J Med. 2007 Jan 18;356(3):311-2. No abstract available.

32.

Reversal of Sjogren's-like syndrome in non-obese diabetic mice.

Tran SD, Kodama S, Lodde BM, Szalayova I, Key S, Khalili S, Faustman DL, Mezey E.

Ann Rheum Dis. 2007 Jun;66(6):812-4. Epub 2006 Dec 19.

33.

Comment on papers by Chong et al., Nishio et al., and Suri et al. on diabetes reversal in NOD mice.

Faustman DL, Tran SD, Kodama S, Lodde BM, Szalayova I, Key S, Toth ZE, Mezey E.

Science. 2006 Nov 24;314(5803):1243; author reply 1243.

34.
35.

Methods to characterize lymphoid apoptosis in a murine model of autoreactivity.

Kühtreiber WM, Kodama S, Burger DE, Dale EA, Faustman DL.

J Immunol Methods. 2005 Nov 30;306(1-2):137-50. Epub 2005 Sep 30.

PMID:
16242708
36.

Regenerative medicine: Stem cell research turns to the spleen.

Faustman DL.

Discov Med. 2005 Oct;5(29):447-9.

37.

The therapeutic potential of tumor necrosis factor for autoimmune disease: a mechanistically based hypothesis.

Kodama S, Davis M, Faustman DL.

Cell Mol Life Sci. 2005 Aug;62(16):1850-62. Review.

PMID:
15968469
38.

Regenerative medicine: a radical reappraisal of the spleen.

Kodama S, Davis M, Faustman DL.

Trends Mol Med. 2005 Jun;11(6):271-6.

PMID:
15949768
39.

Diabetes and stem cell researchers turn to the lowly spleen.

Kodama S, Davis M, Faustman DL.

Sci Aging Knowledge Environ. 2005 Jan 19;2005(3):pe2. Review.

PMID:
15659719
40.

Routes to regenerating islet cells: stem cells and other biological therapies for type 1 diabetes.

Kodama S, Faustman DL.

Pediatr Diabetes. 2004;5 Suppl 2:38-44. Review.

PMID:
15601373
41.

Human pancreatic islet-derived progenitor cell engraftment in immunocompetent mice.

Abraham EJ, Kodama S, Lin JC, Ubeda M, Faustman DL, Habener JF.

Am J Pathol. 2004 Mar;164(3):817-30.

42.

Central role of defective apoptosis in autoimmunity.

Kühtreiber WM, Hayashi T, Dale EA, Faustman DL.

J Mol Endocrinol. 2003 Dec;31(3):373-99. Review.

PMID:
14664701
43.

Islet regeneration during the reversal of autoimmune diabetes in NOD mice.

Kodama S, Kühtreiber W, Fujimura S, Dale EA, Faustman DL.

Science. 2003 Nov 14;302(5648):1223-7.

44.

Role of defective apoptosis in type 1 diabetes and other autoimmune diseases.

Hayashi T, Faustman DL.

Recent Prog Horm Res. 2003;58:131-53. Review.

PMID:
12795417
45.

Polymorphisms of human TAP2 detected by denaturing gradient gel electrophoresis.

Penfornis A, Yan G, Shi L, Faustman DL.

Hum Immunol. 2003 Jan;64(1):156-67.

PMID:
12507827
46.

Impaired processing and presentation by MHC class II proteins in human diabetic cells.

Yan G, Shi L, Penfornis A, Faustman DL.

J Immunol. 2003 Jan 1;170(1):620-7.

47.

Cells for repair: breakout session summary.

Faustman DL, Pedersen RL, Kim SK, Lemischka IR, McKay RD.

Ann N Y Acad Sci. 2002 Jun;961:45-7. No abstract available.

PMID:
12081862
48.

Reversal of established autoimmune diabetes by in situ beta-cell regeneration.

Faustman DL.

Ann N Y Acad Sci. 2002 Jun;961:40. Review. No abstract available.

PMID:
12081859
49.

Analysis of TAP2 polymorphisms in Finnish individuals with type I diabetes.

Penfornis A, Tuomilehto-Wolf E, Faustman DL, Hitman GA; DiMe (Childhood Diabetes in Finland) Study Group.

Hum Immunol. 2002 Jan;63(1):61-70.

PMID:
11916171
50.

Supplemental Content

Loading ...
Support Center